Targeting FcRn for the Generation of Therapeutics
- Cell biological insight into the subcellular trafficking behavior of FcRn and IgG has informed the design of therapeutics
- FcRn inhibitors are now approved for the treatment of antibody-mediated disease
- Different classes of FcRn inhibitors can have distinct behavior at the level of subcellular trafficking